Quick Answer
Chemomab Therapeutics Ltd. reported Total Assets of $13.81 million for the year ending 2025.
- Chemomab Therapeutics Ltd. showed a decrease of -18.6% in Total Assets from 2024 to 2025.
- This data is from Chemomab Therapeutics Ltd.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $15.18 million | Q2 2020: $10.02 million | Q3 2020: $7.69 million | Q1 2021: $60.12 million | Q2 2021: $70.52 million | Q3 2021: $67.44 million | Q1 2022: $60.96 million | Q2 2022: $56.38 million | Q3 2022: $50.22 million | Q1 2023: $35.01 million.
- Over the full 8 years of available data (2018 to 2025), Chemomab Therapeutics Ltd.'s Total Assets has grown by 8.2%.
- Historical annual values: Fiscal year 2025: $13.81 million | Fiscal year 2024: $16.96 million | Fiscal year 2023: $22.15 million | Fiscal year 2022: $43.06 million | Fiscal year 2021: $64.35 million | Fiscal year 2020: $12.48 million | Fiscal year 2019: $19.76 million | Fiscal year 2018: $12.76 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: